|
Expression of FZD2
|
|---|
|
Factors
|
Low (N = 71)
|
High (N = 34)
|
P-value
|
|---|
|
Age (years)
|
|
≤ 50
|
35
|
17
|
1
|
|
> 50
|
36
|
17
| |
|
Tumor size (cm)
|
|
< 2.5
|
31
|
22
|
0.060
|
|
≥ 2.5
|
40
|
12
| |
|
ER status
|
|
(+)
|
35
|
23
|
0.095
|
|
(−)
|
36
|
11
| |
|
PR status
|
|
(+)
|
44
|
20
|
0.832
|
|
(−)
|
27
|
14
| |
|
Her-2 status
|
|
(+)
|
22
|
13
|
0.511
|
|
(−)
|
49
|
21
| |
|
Ki-67 status (%)
|
|
≤ 20%
|
24
|
10
|
0.824
|
|
> 20%
|
47
|
24
| |
|
Pathological grading
|
|
I–II
|
51
|
23
|
0.655
|
|
III
|
20
|
11
| |
|
TNM stage
|
|
I–II
|
57
|
18
|
0.006*
|
|
III–IV
|
14
|
16
| |
|
Lymph-node metastasis
|
|
pN0
|
54
|
18
|
0.024*
|
|
pN+
|
17
|
16
| |
|
Organ metastasis
|
|
No
|
65
|
15
|
0.000*
|
|
Yes
|
6
|
19
| |
- ER estrogen receptor, FZD2 frizzled class receptor 2, Her-2 human epidermal growth factor receptor 2, PR progesterone receptor
- * P < .05 was considered statistically significant
